INTRODUCTION
Medical therapies and radiological adjuvants are currently limited for aggressive meningiomas.
Inhibitors of poly (ADP-ribose) polymerase (PARP), such as ABT-888, plays a role in cancer by preventing DNA repair. PARP inhibitors can improve sensitization to radiation and alkylating treatments in gliomas and other tumors but have not yet been studied in meningiomas. We hypothesize that ABT-888 and radiation therapy combine to show synergistic anti-tumor effects in meningioma cell lines. Furthermore, we hypothesize that this effect is mediated by hypoxia inducible factor 1A (HIF1A).
METHODS
A primary meningioma cell line developed by our lab (GAR-Neg) along with a cell line with a shRNA-HIF1A knockdown (GAR1589) were used. After treatment with ABT-888, TMZ and radiotherapy, cells were evaluated using a cell viability assay (Cell Titer-Glo) and real-time cell microscopy (e.g. Incucyte). Experiments were performed in triplicate and statistically analyzed. 
